A study examining the gut microbiota of HER2-negative metastatic breast cancer patients found distinct differences in composition and function between those receiving metronomic chemotherapy with Capecitabine (n = 15)—a low, minimally toxic dose—and those on a conventional chemotherapy regimen (n = 16). Here, ERBB2 is linked to breast carcinoma.